Show simple item record

dc.contributor.authorChoompoo, N.
dc.contributor.authorBartley, O.J.
dc.contributor.authorPrecious, S.V.
dc.contributor.authorVinh, N.N.
dc.contributor.authorSchnell, C.
dc.contributor.authorGarcia, A.
dc.contributor.authorRoberton, V.H.
dc.contributor.authorWilliams, N.M.
dc.contributor.authorKemp, P.J.
dc.contributor.authorKelly, Claire
dc.contributor.authorRosser, A.E.
dc.date.accessioned2021-05-10T09:57:37Z
dc.date.available2021-05-10T09:57:37Z
dc.date.issued2020-11-25
dc.identifier.citationChoompoo, N., Bartley, O.J., Precious, S.V., Vinh, N.N., Schnell, C., Garcia, A., Roberton, V.H., Williams, N.M., Kemp, P.J., Kelly, C.M. and Rosser, A.E. (2021) 'Induced pluripotent stem cells derived from the developing striatum as a potential donor source for cell replacement therapy for Huntington disease', Cytotherapy, 23(2), pp.111-118. https://doi.org/10.1016/j.jcyt.2020.06.001en_US
dc.identifier.issn1465-3249
dc.identifier.issn1477-2566 (electronic)
dc.identifier.urihttp://hdl.handle.net/10369/11391
dc.descriptionArticle published in Cytotheraoy available open access at https://doi.org/10.1016/j.jcyt.2020.06.001en_US
dc.description.abstractBackground Cell replacement therapy (CRT) for Huntington disease (HD) requires a source of striatal (STR) progenitors capable of restoring the function lost due to STR degeneration. Authentic STR progenitors can be collected from the fetal putative striatum, or whole ganglionic eminence (WGE), but these tissues remain impractical for widespread clinical application, and alternative donor sources are required. Here we begin exploring the possibility that induced pluripotent stem cells (iPSC) derived from WGE may retain an epigenetic memory of their tissue of origin, which could enhance their ability to differentiate into STR cells. Results We generate four iPSC lines from human WGE (hWGE) and establish that they have a capacity similar to human embryonic stem cells with regard to their ability to differentiate toward an STR phenotype, as measured by expression and demethylation of key STR genes, while maintaining an overall different methylome. Finally, we demonstrate that these STR-differentiated hWGE iPSCs share characteristics with hWGE (i.e., authentic STR tissues) both in vitro and following transplantation into an HD model. Overall, iPSCs derived from human WGE show promise as a donor source for CRT for HD.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesCytotherapy;
dc.titleInduced pluripotent stem cells derived from the developing striatum as a potential donor source for cell replacement therapy for Huntington diseaseen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1016/j.jcyt.2020.06.001
dcterms.dateAccepted2020-06-16
rioxxterms.funderCardiff Metropolitan Universityen_US
rioxxterms.identifier.projectCardiff Metropolian (Internal)en_US
rioxxterms.versionNAen_US
rioxxterms.funder.project37baf166-7129-4cd4-b6a1-507454d1372een_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record